New Purdue opioid crisis settlement builds ‘momentum' for Canada: B.C. AG

Recent settlements in U.S. government lawsuits against opioid manufacturer Purdue Pharma and the firm that allegedly consulted on boosting its sales have B.C.'s attorney general feeling 'heartened' as she pursues similar lawsuits in Canada.
Monday saw 55 U.S. states and territories reach a US$7.5-billion settlement with Purdue, the maker of OxyContin, and members of the Sackler family that sought to hold them accountable for contributing to the opioid overdose crisis.
As part of the settlement, the Sacklers will give up their control of the bankrupt company and will be barred from selling prescription opioids in the future.
A federal judge said Wednesday that he will rule Friday on a plan for local governments and individual victims, who would also be entitled to compensation, to vote on approving the settlement by September, allowing it to proceed.
Story continues below advertisement
The announcement of the U.S. settlement came after the B.C. Supreme Court on Friday certified a class-action lawsuit by the province against McKinsey & Company, which is accused of advising Purdue and other drugmakers on how to market their opioid products in Canada.
McKinsey has already had to pay over US$1 billion in penalties to settle similar lawsuits in the U.S., which also led to jail time for a McKinsey executive.
'I'm really pleased with the momentum,' B.C. Attorney General Niki Sharma told Global News in an interview.
'My job as attorney general is to make sure we pursue it very aggressively and as quickly as we can, so I am heartened by the success in the States and will keep on leading the charge here in Canada.'
The B.C. lawsuit against McKinsey is separate from a larger class action against dozens of opioid manufacturers and distributors on allegations they downplayed the risk their products posed in order to rake in profits. That lawsuit was allowed to go ahead last fall and was certified in January.
2:00
Supreme Court upholds B.C. opioid lawsuit
B.C. is leading both lawsuits on behalf of the other Canadian provinces and territories and the federal government, with the goal of recovering health-care costs that went toward responding to the overdose crisis, Sharma said.
Story continues below advertisement
'We think it's unfair that companies that profited so much, knowing that their product was so harmful and that would cause this level of addiction, aren't paying for the costs of health care,' she said.
A spokesperson for McKinsey told Global News it intends to defend itself against the lawsuit, which the company says is without merit.
'McKinsey did not undertake any work in Canada to enhance the sale or marketing of opioids,' the spokesperson said in an email.
Alleged tactics to 'turbocharge' opioid sales
B.C.'s lawsuit against McKinsey alleges the Canadian subsidiaries of Purdue, as well as Johnson & Johnson, Janssen and other drugmakers, employed many of the same tactics used by U.S. parent companies to boost their sales.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
The B.C. Supreme Court, in certifying the lawsuit, noted in its decision that multinational companies often apply business and marketing strategies 'universally.'
Story continues below advertisement
Last December, McKinsey agreed to pay U$650 million to resolve a U.S. Justice Department lawsuit that focused on the firm's work with Purdue, including allegations that McKinsey advised on steps to 'turbocharge' sales of OxyContin.
Martin Elling, a former McKinsey senior partner who worked on Purdue matters, was sentenced to six months in prison after pleading guilty to obstruction of justice related to that case.
2:42
Conservatives grill Trudeau on former McKinsey head connection ahead of committee appearance
The federal settlement was on top of a combined US$641 million McKinsey agreed to pay in 2021 to resolve similar claims brought by U.S. state attorneys general.
In total, federal and state lawsuits related to the opioid crisis have resulted in roughly US$50 billion in settlements, according to researchers from Johns Hopkins University who track such claims.
Long-term heavy use of prescription painkillers like OxyContin due to dependence contributed to a majority of opioid-related hospitalizations and overdoses in the early 2000s across North America. In recent years, illicit opioids like fentanyl have overtaken prescription opioids as the primary driver of the opioid crisis.
Story continues below advertisement
Between 2016 and last September, nearly 51,000 Canadians have died of an opioid-related overdose, according to federal data. B.C., which declared a public health emergency in 2016, saw the most fatal overdoses of any other province during that time, with more than 16,000 deaths.
'I think like many provinces across this country, we've really seen the toll of the opioid crisis on people not only with long-lasting addictions and impacts there, but loss of life and a lot of people that are mourning the loss of their loved ones,' Sharma said.
A spokesperson for Health Canada said the federal government 'believes companies should be held accountable for their role in the overdose crisis' and will continue to work with provinces and territories on B.C.'s legal actions.
'The overdose crisis continues to be one of Canada's most pressing public health challenges,' the spokesperson said in an email to Global News.
Health Canada is reviewing and 'considering' developments from the recent Purdue settlement in the U.S., the statement added.
Where should the money go?
In 2022, B.C. secured a $150-million settlement on behalf of Canadian governments in a class action against Purdue. The settlement was finalized in early 2023, allowing individuals to submit claims from a $20-million portion set aside for victims and their families, a process that remains ongoing.
Story continues below advertisement
The pending lawsuit against opioid manufacturers and distributors names Purdue and its various subsidiaries, as well as Johnson & Johnson, Janssen and Canadian companies like Loblaw and its subsidiary Shoppers Drug Mart. It remains in litigation.
5:09
B.C. government steps up legal action against opioid drug makers
Researchers writing in the International Journal of Drug Policy earlier this year urged Canadian governments to ensure funds recovered from opioid lawsuit settlements go directly toward combating the drug crisis, rather than unrelated government expenses.
Those measures should include funding harm reduction services like overdose prevention centres and safe drug supplies, as well as community organizations that work directly with people suffering from addiction, the paper says.
Efforts to track how U.S. state and local governments are spending their opioid settlement money have uncovered several examples of funds not being used to directly respond to the opioid crisis.
Story continues below advertisement
Canada is being urged to avoid similar 'pitfalls' by mandating that at least 85 per cent of recovered funds be allocated to 'opioid remediation efforts,' and working directly with community organizations and members affected by addiction.
Proposed guidelines by researchers at Johns Hopkins University for how U.S. opioid settlement funds should be spent have been adopted in over 25 states, according to the university.
Sharma said B.C.'s lawsuits are structured so that any funds recovered by the province will be mandated to go to the health-care system, but that could evolve depending on how settlements are structured.
'It may be that as this develops, and the opioid cases develop, it will be tied to organizations that do addictions treatment, or there could be a whole range of things that go directly towards this crisis,' she said.
She pointed to the record $32.5-billion settlement B.C. won in March on behalf of Canadian governments in its lawsuit against the tobacco industry as a model both of the province's health-related legal advocacy and the results it can achieve.
'We are really focused on eliminating the bad actors,' she said.
'It's really important to make sure that we set a line in the sand about what's right and what isn't right with the conduct of all companies out there.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CTV News

41 minutes ago

• CTV News

Jeep maker Stellantis weighs sale among options for Maserati, sources tell Reuters

The Stellantis sign is seen outside the Chrysler Technology Center, Jan. 19, 2021, in Auburn Hills, Mich., on April 26, 2023. (AP Photo/Carlos Osorio) MILAN - Stellantis is considering a possible sale of its struggling luxury Maserati unit, among other options, two sources with knowledge of the matter said, as the automaker seeks to overhaul its sprawling portfolio of 14 brands. Discussions over Maserati's future started before new CEO Antonio Filosa, who starts on Monday, was appointed last month, while Stellantis was steered by Chair John Elkann. The viability of the French-Italian company's 14 brands - which include Chrysler, Peugeot, Jeep and Alfa Romeo - was a priority for Elkann as he interviewed candidates to fill the CEO job. Like other European carmakers, the world's fourth biggest automaker is facing hefty U.S. import tariffs imposed by U.S. President Donald Trump and struggling with stiff competition from Chinese rivals. Stellantis hired consultant McKinsey early in April to advise it on the effects of the U.S. tariffs on Maserati and Alfa Romeo as the two brands prepare future plans. Stellantis affirmed then that it was fully committed to both brands. However, a possible divestment of Maserati, its only luxury brand, is among the options McKinsey is exploring for Stellantis, the two sources told Reuters, adding the adviser's assessment was still in the early stages. They spoke on condition of anonymity because they were not authorized to discuss the matter publicly. Asked for comment, a Stellantis spokesperson said: 'Respectfully, Maserati is not for sale.' McKinsey declined to comment. Filosa's predecessor Carlos Tavares, who resigned in December after a poor performance in the U.S. market, had refused to consider getting rid of any of the carmaker's brands. But some investors and analysts say a streamlined portfolio would boost Stellantis' profit margins. Stellantis shares have lost two-thirds of their value since March last year. Falling sales Maserati's sales fell by more than half in 2024 to just 11,300 units and the unit posted an adjusted operating loss of 260 million euros ($298 million) last year. The brand currently has no new model launches scheduled as it waits for a new business plan, after its previous one was put on hold by Stellantis last year. Brand head Santo Ficili said earlier this month the plan would be presented soon after Filosa starts the job. One of the sources said Stellantis has been coming to terms with the fact that it has too many brands, making it difficult for it to properly invest in all of them. The carmaker needs to 'set priorities,' the source said. Stellantis has not specifically mandated McKinsey to find a buyer for Maserati, but the mandate is to consider all options, including a potential sale, the second source said. All options are on the table, the source said. Stellantis' board has been divided over plans for Maserati, one source said. Some board members think Stellantis is not in a position to sustainably re-launch Maserati and suggest selling it is the best option. Others think Maserati still has value and that selling its only luxury brand would be a huge reputational setback for Stellantis. Chinese automakers, such as Chery, might be among those interested in buying European auto brands, to support their expansion in the region, where they still lack brand recognition among consumers. This would be a similar move to SAIC's purchase of Britain's MG Motor or Geely's acquisition of Sweden's Volvo Cars in 2010. Reporting by Giulio Piovaccari; Editing by Nick Carey and Emelia Sithole-Matarise, Reuters

National Observer

43 minutes ago

• National Observer

Quebec dials back emissions projections, blaming global uncertainty

The Quebec government is scaling back its projections for greenhouse gas emissions reductions due to the Trump administration. A report published Thursday by the province's Environment Department says the current US government has created a "challenging environment for advancing climate action." It points in particular to US President Donald Trump 's decision to impose tariffs, which it says have slowed down business investment, including in decarbonization. It also says the administration's attempts to challenge carbon pricing mechanisms in various US states were "exerting downward pressure on market prices." "The economic and political uncertainty caused by the new US federal administration ... does not allow the deployment of measures as quickly and effectively as planned," the report says. The government now estimates that measures being adopted in Quebec to reduce emissions will account for 65 per cent of the cuts needed to reach the province's 2030 emissions target, down from a projected 67 per cent last year. Quebec is aiming to reduce greenhouse gas emissions by 37.5 per cent compared to 1990 levels by 2030. That's a drop of about 30 million tonnes from projected emissions in the absence of climate policies. The new report is an annual update on the province's progress toward meeting that goal. It estimates that planned measures will cut emissions by 19.4 million tonnes in 2030, a slight drop from last year's projections. The document also says the Canadian government's decision to scrap the federal consumer carbon price in April could harm the competitiveness of Quebec businesses. "Uncertainty remains regarding the actions that will be taken by the federal government to combat climate change," it reads. Quebec has so far maintained its own cap-and-trade carbon pricing system, which is linked with California's system. The report says Quebec's carbon price is a major driver of emissions reductions in the province, and revenue from the carbon market is an important source of funding for other climate measures in the government's plan. The report highlights $10.1 billion in planned government spending over the next five years, much of it to reduce emissions from transportation, industry and housing. It says new initiatives under development could lead to further emissions cuts and could get the province to between 67 and 72 per cent of its 2030 target. Despite dialling back its projections, the government says greenhouse gas emissions dropped by 0.9 million tonnes in Quebec between 2022 and 2023, and have not returned to pre-pandemic levels. The report also says there was a record number of electric-vehicle sales in Quebec in 2024, with more than 125,000 new registrations. Zero-emission vehicle sales made up nearly 31 per cent of light-duty vehicle sales that year, it says, and there were 375,000 electric vehicles on the road in Quebec last December. This report by The Canadian Press was first published June 19, 2025.

Cision Canada

an hour ago

• Cision Canada

With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology

VANCOUVER, BC, June 20, 2025 /CNW/ -- USA News Group News Commentary – The costs of cancer drugs is skyrocketing, according to a recent report from Bloomberg. Analysts at Nova One Advisor estimate that the global oncology drugs market will grow at a 7.4% CAGR through to US$366.24 billion by 2034. Help doesn't appear to be coming from the public sector, as reports state that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For investors to note, plenty of oncology innovators have provided recent developments, including Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Immuneering Corporation (NASDAQ: IMRX), GRAIL, Inc. (NASDAQ: GRAL), Intensity Therapeutics, Inc. (NASDAQ: INTS), and Relay Therapeutics, Inc. (NASDAQ: RLAY). The global oncology market is expected to see strong growth over the next decade, with ResearchAndMarkets forecasting it to reach US$866.1 billion by 2034 at a 10.8% CAGR. A separate estimate from Vision Research Reports projects the market will surpass US$903.81 billion by the same year, growing at a 10.9% CAGR. Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC) has entered a new phase of leadership with the appointment of Jared Kelly as Chief Executive Officer and member of the Board. Kelly brings a background in high-stakes biotech transactions and strategic immuno-oncology development, positioning him to guide the company through its next stage of clinical and business evolution. Before joining Oncolytics, Kelly served as General Counsel at Ambrx Biopharma, where he played a key role in its $2 billion acquisition by Johnson & Johnson. His earlier work includes advising life sciences firms on licensing, partnerships, and M&A while at Kirkland & Ellis LLP and Lowenstein Sandler LLP. Now leading Oncolytics, he steps into a company advancing pelareorep, a virus-based immunotherapeutic designed to work synergistically with checkpoint inhibitors and other agents across a range of solid and blood cancers. "Pelareorep's clinical data across multiple tumors is striking and represents the potential for a true backbone immunotherapy to address many in-need indications. Importantly, the data show that pelareorep creates a robust immunologic response in difficult tumors and increases survival in a patient population where survival has historically evaded most patients," said Jared Kelly, CEO of Oncolytics Biotech. "With a renewed focus and sharpened clinical development plan, we believe we will move pelareorep forward effectively and efficiently to a place where potential partners will see the value of a de-risked immunotherapy. I am excited to get to work accelerating development and unlocking significant value for stakeholders." Kelly's appointment signals a clear strategic focus: advancing pelareorep toward key late-stage milestones through a capital-conscious approach that remains open to strategic collaboration. Pelareorep currently holds FDA Fast Track designation for both metastatic pancreatic ductal adenocarcinoma (mPDAC) and HR+/HER2- metastatic breast cancer (mBC) —a rare dual recognition that underscores its regulatory momentum. Across multiple studies, the virus-based therapy has demonstrated consistent immune activation, broad combinability with checkpoint inhibitors and chemotherapies, and encouraging response rates in challenging cancer types. In mPDAC, pelareorep has achieved over 60% objective response rates in tumor-evaluable patients across Phase 1 and 2 trials—more than double what's typically seen in historical benchmarks. Separate analyses also reported two-year survival rates four to six times higher than control arms or prior studies. In HR+/HER2- mBC, two randomized Phase 2 trials (IND-213 and BRACELET-1) showed survival benefits supportive of further investigation. Meanwhile, a Phase 2 cohort in anal cancer pairing pelareorep with a checkpoint inhibitor reported partial or complete responses in nearly half of evaluable patients—substantially higher than historical norms for monotherapy in this setting. "Mr. Kelly's vision and track record is an extraordinary fit with the standout clinical data pelareorep has generated to date," said Wayne Pisano, Chair of the Board and outgoing Interim CEO of Oncolytics. "We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize Oncolytics' potential to deliver transformative outcomes for patients and exceptional value for investors." Kelly's compensation package includes equity grants and milestone-linked incentives tied to future financings and potential strategic transactions—aligning leadership priorities with long-term shareholder interests. The structure signals a commitment to advancing both clinical and corporate goals while preserving balance sheet discipline and maintaining appeal for potential partners. With multiple cohorts progressing in the GOBLET study—including those in pancreatic and anal cancer supported by external funding and regulatory engagement— Oncolytics is positioned to move forward with a combination of scientific momentum, financial agility, and renewed strategic focus. In other recent industry developments and happenings in the market include: Immuneering Corporation (NASDAQ: IMRX) reported positive Phase 2a data for atebimetinib (IMM-1-104) in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. At six months, the study showed 94% overall survival and 72% progression-free survival in 34 patients, with no median OS or PFS reached yet. "These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer," said Ben Zeskind, Ph.D., Co-founder and CEO of Immuneering. "Our ultimate goal is to help cancer patients outlive their disease, and today's announcement represents an important milestone on that journey." The combination also demonstrated a 39% overall response rate, an 81% disease control rate, and a notably favorable tolerability profile. Many patients experienced deep, durable tumor regressions, including lesions rendered undetectable. The regimen was well tolerated, with an adverse event profile suggesting potential best-in-class positioning among MEK inhibitors. GRAIL, Inc. (NASDAQ: GRAL), recently announced strong top-line results from the PATHFINDER 2 registrational study evaluating its Galleri® multi-cancer early detection test in over 25,000 adults. "We are delighted to see very encouraging performance of the Galleri MCED test as a cancer screening tool in broad intended use populations of asymptomatic adults over 50 years of age in both the PATHFINDER 2 study and the NHS-Galleri trial's prevalent screening round," said Josh Ofman, MD, MSHS, President at GRAIL. "We would like to extend our sincere gratitude to all of the participants and investigators in both of these pivotal studies, who are collectively helping to realize the potential of this groundbreaking technology for population-scale multi-cancer early detection and move the field forward." The study showed a substantially higher positive predictive value (PPV) compared to the original PATHFINDER trial, with consistent specificity and cancer signal origin accuracy, and no serious safety concerns reported. GRAIL plans to submit these results to the FDA as part of its ongoing premarket approval process under Breakthrough Device Designation. Intensity Therapeutics, Inc. (NASDAQ: INTS) announced that the first patients in its ongoing Phase 2 INVINCIBLE-4 trial achieved high levels of tumor necrosis within eight days of receiving two doses of INT230-6, before starting standard-of-care immunochemotherapy for triple-negative breast cancer (TNBC). "We are excited to see that INT230-6 is achieving meaningful levels of necrosis in patients with evidence of immune activation," said Lewis H. Bender, President and CEO of Intensity. "TNBC patients risk their lives to achieve a pCR, and about forty percent fail to achieve the desired result." MRI scans showed substantial tumor destruction and inflammation, suggesting immune activation following direct intratumoral injection. The randomized study compares INT230-6 followed by standard treatment versus standard treatment alone, with pathological complete response (pCR) as the primary endpoint. Relay Therapeutics, Inc. (NASDAQ: RLAY) reported updated interim data from its Phase 1/2 study of RLY-2608 plus fulvestrant, showing a median progression-free survival (PFS) of 11.0 months in second-line patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. "We are encouraged by the consistency of these updated RLY-2608 + fulvestrant data, which continue to show the potential benefit of a mutant-selective PI3Kα inhibitor for improving both the tolerability profile and progression free survival compared to standard of care," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We look forward to starting the first mutant-selective PI3Kα Phase 3 trial, ReDiscover-2, in the middle of this year." Among patients at the recommended Phase 3 dose, the clinical benefit rate reached 67%, and 39% had confirmed partial responses, with notably higher response rates in those with kinase mutations. The combination maintained a favorable tolerability profile, with low rates of high-grade adverse events and minimal treatment discontinuations. DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Oncolytics Biotech Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares of Oncolytics Biotech Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Oncolytics Biotech Inc. which were purchased in the open market, and reserve the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Oncolytics Biotech Inc.; this is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.